Borer Denton & Associates Inc. Trims Stock Position in CVS Health Co. (NYSE:CVS)

Borer Denton & Associates Inc. lowered its holdings in CVS Health Co. (NYSE:CVS) by 30.2% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 34,203 shares of the pharmacy operator’s stock after selling 14,807 shares during the quarter. Borer Denton & Associates Inc.’s holdings in CVS Health were worth $1,535,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. TD Private Client Wealth LLC raised its stake in shares of CVS Health by 28.7% in the third quarter. TD Private Client Wealth LLC now owns 46,938 shares of the pharmacy operator’s stock valued at $2,951,000 after acquiring an additional 10,465 shares in the last quarter. Principal Financial Group Inc. lifted its stake in CVS Health by 4.8% in the third quarter. Principal Financial Group Inc. now owns 1,434,476 shares of the pharmacy operator’s stock worth $90,200,000 after acquiring an additional 66,244 shares during the last quarter. Hall Laurie J Trustee increased its position in shares of CVS Health by 25,484.4% in the 4th quarter. Hall Laurie J Trustee now owns 11,513 shares of the pharmacy operator’s stock valued at $517,000 after purchasing an additional 11,468 shares during the last quarter. B&D White Capital Company LLC acquired a new position in shares of CVS Health during the 4th quarter worth about $417,000. Finally, TOMS Capital Investment Management LP acquired a new stake in shares of CVS Health during the 3rd quarter worth about $121,987,000. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at CVS Health

In other news, SVP James David Clark sold 7,513 shares of the company’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $66.35, for a total transaction of $498,487.55. Following the completion of the transaction, the senior vice president now directly owns 8,394 shares of the company’s stock, valued at $556,941.90. This represents a 47.23 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Michael F. Mahoney bought 30,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The stock was acquired at an average cost of $66.70 per share, with a total value of $2,001,000.00. Following the transaction, the director now owns 39,356 shares of the company’s stock, valued at $2,625,045.20. This represents a 320.65 % increase in their position. The disclosure for this purchase can be found here. Insiders own 0.24% of the company’s stock.

CVS Health Stock Down 1.5 %

Shares of CVS opened at $66.54 on Wednesday. CVS Health Co. has a 12 month low of $43.56 and a 12 month high of $80.75. The stock has a market cap of $83.89 billion, a price-to-earnings ratio of 18.18, a P/E/G ratio of 0.98 and a beta of 0.54. The company has a 50-day moving average price of $61.22 and a two-hundred day moving average price of $57.46. The company has a quick ratio of 0.60, a current ratio of 0.81 and a debt-to-equity ratio of 0.80.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Wednesday, February 12th. The pharmacy operator reported $1.19 EPS for the quarter, topping analysts’ consensus estimates of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. Equities analysts predict that CVS Health Co. will post 5.89 EPS for the current fiscal year.

CVS Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, May 1st. Investors of record on Tuesday, April 22nd will be paid a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a yield of 4.00%. The ex-dividend date of this dividend is Tuesday, April 22nd. CVS Health’s payout ratio is 72.68%.

Analysts Set New Price Targets

A number of analysts have weighed in on CVS shares. Leerink Partners raised shares of CVS Health from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $55.00 to $75.00 in a report on Thursday, February 13th. Evercore ISI boosted their price target on shares of CVS Health from $60.00 to $65.00 and gave the company an “outperform” rating in a research report on Monday, January 27th. Barclays raised their price objective on CVS Health from $71.00 to $73.00 and gave the stock an “overweight” rating in a report on Thursday, February 13th. Wolfe Research boosted their price objective on CVS Health from 67.00 to 70.00 and gave the company an “overweight” rating in a research note on Tuesday, February 11th. Finally, Leerink Partnrs upgraded shares of CVS Health from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 12th. Four investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $70.39.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.